Adaptive Biotechnologies (NASDAQ: ADPT) Posts Q1 2026 Loss of $0.13 Per Share

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) reported a Q1 2026 net loss of $20 million, or $0.13 per share, as shares fell $0.72 (4.97%) to $13.78 on the session. The results, confirmed via an SEC 8-K filing dated May 5, 2026 under Item 2.02, reflect the company's continued investment phase as it scales its commercial operations.

Q1 2026 At a Glance

• Net loss: $20 million for the quarter
• Loss per share: $0.13
• Revenue growth (YoY): 51.0%, reflecting strong commercial-stage momentum
• Gross margin: 74.2%, indicating a capital-efficient product mix
• Operating margin: -17.8%, consistent with an active investment cycle
• Net margin: -21.5%
• Market capitalization: $2.2 billion
• 52-week range: $8.38 – $20.76; current price $13.78

What Drove the Results

ADPT's 51% year-over-year revenue growth stands out as the headline operational achievement, suggesting meaningful uptake of its adaptive immune system diagnostics platform. The company's 74.2% gross margin reinforces that the underlying business model carries strong unit economics, even as operating costs keep the bottom line in deficit territory.

The -17.8% operating margin reflects deliberate spending to support commercial-stage expansion — a pattern typical of biotechnology companies at this stage of development. With a forward P/E of -51.3x, the market is pricing ADPT on the expectation of future profitability rather than near-term net income.

Wall Street View

Analyst sentiment toward ADPT remains firmly constructive and unchanged from the prior month. As of May 1, 2026, the consensus stands at 5 Strong Buy, 7 Buy, and 2 Hold, with zero Sell or Strong Sell ratings — identical to the April 1, 2026 distribution. The absence of any rating downgrades following the Q1 report suggests Wall Street views the current loss profile as consistent with expectations.

Investor Takeaway

Adaptive Biotechnologies (NASDAQ: ADPT) presents a profile that balances a notable near-term net loss against 51% revenue growth and a 74.2% gross margin, attributes that have sustained broad analyst support across 14 Buy-equivalent ratings. Investors should weigh the company's strong commercial trajectory against its ongoing cash consumption, as reflected in the -17.8% operating margin. No analyst price targets were available at the time of publication, but the unchanged consensus following the Q1 release signals measured confidence in the company's direction.